Startseite>>Signaling Pathways>> GPCR/G protein>> mAChR>>VU0238441

VU0238441

Katalog-Nr.GC61378

VU0238441 ist ein panmuskarinischer Acetylcholinrezeptor (mAChR) positiver allosterischer Modulator (PAM) mit EC50s von 3,2 μM, 2,8 μM, 2,2 μM, 2,1 μM, >10 μM fÜr M1, M2, M3, M5 bzw. M4[ 2].

Products are for research use only. Not for human use. We do not sell to patients.

VU0238441 Chemische Struktur

Cas No.: 85511-68-8

Größe Preis Lagerbestand Menge
5mg
46,00 $
Auf Lager
10mg
65,00 $
Auf Lager
25mg
121,00 $
Auf Lager
50mg
167,00 $
Auf Lager
100mg
232,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

VU0238441 is a pan muscarinic acetylcholine receptor (mAChR) positive allosteric modulator (PAM) with EC50s of 3.2 μM, 2.8 μM, 2.2 μM, 2.1 μM, >10 μM for M1, M2, M3, M5 and M4, respectively[1][2].

VU0238441 is an analogue of VU0119498[2].

[1]. Thomas M Bridges, et al. Chemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM. Bioorg Med Chem Lett. 2010 Jan 15;20(2):558-62. [2]. Thomas M Bridges, et al. Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. J Med Chem. 2009 Jun 11;52(11):3445-8.

Bewertungen

Review for VU0238441

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for VU0238441

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.